MX391191B - Composiciones de liberación extendida de onapristona y métodos. - Google Patents

Composiciones de liberación extendida de onapristona y métodos.

Info

Publication number
MX391191B
MX391191B MX2017005163A MX2017005163A MX391191B MX 391191 B MX391191 B MX 391191B MX 2017005163 A MX2017005163 A MX 2017005163A MX 2017005163 A MX2017005163 A MX 2017005163A MX 391191 B MX391191 B MX 391191B
Authority
MX
Mexico
Prior art keywords
extended
onapristone
release
methods
formulations
Prior art date
Application number
MX2017005163A
Other languages
English (en)
Spanish (es)
Other versions
MX2017005163A (es
Inventor
Alexander Zukiwski
Stefan Proniuk
Original Assignee
Context Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Context Biopharma Inc filed Critical Context Biopharma Inc
Publication of MX2017005163A publication Critical patent/MX2017005163A/es
Publication of MX391191B publication Critical patent/MX391191B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2017005163A 2014-11-17 2015-11-16 Composiciones de liberación extendida de onapristona y métodos. MX391191B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462080868P 2014-11-17 2014-11-17
PCT/US2015/060940 WO2016081383A1 (en) 2014-11-17 2015-11-16 Onapristone extended-release compositions and methods

Publications (2)

Publication Number Publication Date
MX2017005163A MX2017005163A (es) 2018-01-18
MX391191B true MX391191B (es) 2025-03-21

Family

ID=56014429

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005163A MX391191B (es) 2014-11-17 2015-11-16 Composiciones de liberación extendida de onapristona y métodos.

Country Status (11)

Country Link
US (3) US10786461B2 (enExample)
EP (1) EP3247362A4 (enExample)
JP (1) JP6655075B2 (enExample)
KR (1) KR20170084086A (enExample)
CN (2) CN113559075A (enExample)
AU (2) AU2015350241B2 (enExample)
CA (1) CA2966753A1 (enExample)
HK (1) HK1246653A1 (enExample)
MX (1) MX391191B (enExample)
RU (1) RU2017112748A (enExample)
WO (1) WO2016081383A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391191B (es) 2014-11-17 2025-03-21 Context Biopharma Inc Composiciones de liberación extendida de onapristona y métodos.
CA2998924A1 (en) 2015-09-25 2017-03-30 Context Biopharma Inc. Methods of making onapristone intermediates
US10548905B2 (en) 2015-12-15 2020-02-04 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780461A (en) 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
ES533260A0 (es) 1983-06-15 1985-02-01 Schering Ag Procedimiento para la preparacion de 13a-alquilgonanos
DE3321826A1 (de) 1983-06-15 1984-12-20 Schering AG, 1000 Berlin und 4709 Bergkamen 13(alpha)-alkylgonane, deren herstellung und diese enthaltende pharmazeutische praeparate
US4742000A (en) 1986-05-02 1988-05-03 University Of Chicago Antibody to human progesterone receptor and diagnostic materials and methods
DE3630030A1 (de) 1986-09-01 1988-03-03 Schering Ag 13(alpha)-alkylgonan-(delta)(pfeil hoch)9(pfeil hoch)(pfeil hoch)((pfeil hoch)(pfeil hoch)1(pfeil hoch)1(pfeil hoch))(pfeil hoch)-5,10-epoxide
US4774236A (en) 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
IE60780B1 (en) 1987-01-23 1994-08-10 Akzo Nv New 11-aryl steroid derivatives
DE3822770A1 (de) 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
US5283190A (en) 1989-07-31 1994-02-01 Traish Adbulmaged M Specific monoclonal antibodies against a defined epitope of progesterone receptor and methods for their use
DE4008584A1 (de) 1990-03-15 1991-09-26 Schering Ag Verfahren zur herstellung von zwischenprodukten fuer die antigestagensynthese (onapristonsynthese)
US5141961A (en) 1991-06-27 1992-08-25 Richrdson-Vicks Inc. Process for solubilizing difficulty soluble pharmaceutical actives
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
CN1053450C (zh) 1992-11-19 2000-06-14 北京第三制药厂 17位取代11β－取代芳香基－4,9－雌甾二烯类化合物的全合成法
DE4332283A1 (de) 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
HU226566B1 (en) 1994-10-24 2009-04-28 Schering Ag Use of competitive progesterone antagonists for producing pharmaceutical compositions for regulating female fertility as required
US5759577A (en) 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
US5962444A (en) 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6537584B1 (en) 1999-11-12 2003-03-25 Macromed, Inc. Polymer blends that swell in an acidic environment and deswell in a basic environment
NZ522444A (en) 2000-05-19 2004-09-24 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
UY26966A1 (es) 2000-10-18 2002-06-20 Schering Ag Uso de antiprogestinas para la inducción de apoptosis en una célula
US7381976B2 (en) 2001-03-13 2008-06-03 Triton Thalassic Technologies, Inc. Monochromatic fluid treatment systems
AUPR546801A0 (en) 2001-06-05 2001-06-28 Commonwealth Scientific And Industrial Research Organisation Recombinant antibodies
US7105642B2 (en) 2001-08-03 2006-09-12 Cell Signalling Technology, Inc. Monoclonal antibodies specific for phosphorylated estrogen receptor alpha (Ser118) and uses thereof
US20040121304A1 (en) 2001-12-21 2004-06-24 Ulrike Fuhrmann Method for screening for progesterone receptor isoform-specific ligands and for tissue-selective progesterone receptor ligands
EP1613640A4 (en) 2003-02-28 2010-05-19 Us Gov Health & Human Serv PROCESS FOR PREPARING 17 ALPHA-ACETOXY-11 BETA- (4-N, N-DIMETHYLAMINOPHENYL) -19-NORPREGNA-4,9-DIENE-3,20-DION, INTERMEDIATE PRODUCTS AND METHOD OF MANUFACTURING THESE INTERMEDIATE PRODUCTS
US20040265371A1 (en) 2003-06-25 2004-12-30 Looney Dwayne Lee Hemostatic devices and methods of making same
US7247625B2 (en) * 2003-10-09 2007-07-24 Wyeth 6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators
DE602005026290D1 (de) 2004-07-09 2011-03-24 Population Council Inc Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren
US20060063190A1 (en) 2004-09-22 2006-03-23 Tripath Imaging, Inc Methods and compositions for evaluating breast cancer prognosis
WO2006111856A1 (en) 2005-04-20 2006-10-26 Pfizer Limited Pyrazole derivatives as progesterone receptor antagonists
WO2007078599A2 (en) 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
US20070167971A1 (en) 2006-01-17 2007-07-19 Raymond Huey Devices and methods for promoting the formation of blood clots in esophageal varices
US20070166372A1 (en) 2006-01-19 2007-07-19 Mai De Ltd. Preparation of solid coprecipitates of amorphous valsartan
PL1989217T4 (pl) 2006-02-17 2013-02-28 Janssen Pharmaceutica Nv 11-fosforowe pochodne steroidowe użyteczne jako modulatory receptora progesteronu
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
CN101668739A (zh) 2007-04-24 2010-03-10 帝斯曼知识产权资产管理有限公司 用于制造前维生素d的光化学方法
CA2596204C (en) 2007-08-07 2019-02-26 Historx, Inc. Method and system for determining an optimal dilution of a reagent
WO2009025759A1 (en) 2007-08-17 2009-02-26 Progenics Pharmaceuticals (Nevada), Inc. Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
CN101820916A (zh) * 2007-10-12 2010-09-01 诺瓦提斯公司 包含鞘氨醇1磷酸(s1p)受体调节剂的组合物
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
CN103467554A (zh) 2008-02-05 2013-12-25 哈博生物科学公司 药学固体形式
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
TW201002736A (en) 2008-04-28 2010-01-16 Repros Therapeutics Inc Compositions and methods for treating progesterone-dependent conditions
JP5174952B2 (ja) 2009-03-27 2013-04-03 株式会社小松製作所 作業車両の省燃費制御装置および作業車両の省燃費制御方法
WO2010126590A1 (en) 2009-04-27 2010-11-04 Cold Spring Harbor Laboratory Ptp1b inhibitors
WO2010141485A1 (en) 2009-06-01 2010-12-09 Samuel Waxman Cancer Research Foundation Compositions and methods to induce differentiation and growth inhibition in breast cancer
RU2543721C2 (ru) 2009-07-15 2015-03-10 СиТиАй БИОФАРМА КОРП. Цитратная соль 9е-15-(2-пирролидин-1-ил-этокси)-7,12,25-триокса-19,21,24-триазатетрацикло[18.3.1.1(2,5).1(14,18)]гексакоза-1(24),2,4,9,14,16,18(26),20,22-нонаена
US20110293511A1 (en) * 2009-09-29 2011-12-01 Terrance Grant Johns Specific binding proteins and uses thereof
US8261855B2 (en) * 2009-11-11 2012-09-11 Flanders Electric, Ltd. Methods and systems for drilling boreholes
US9295649B2 (en) 2009-12-15 2016-03-29 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
WO2011119194A1 (en) * 2010-03-22 2011-09-29 Repros Therapeutics Inc. Compositions and methods for non-toxic delivery of antiprogestins
EP2638163B1 (en) 2010-11-12 2017-05-17 The General Hospital Corporation Polycomb-associated non-coding rnas
EP2651400B2 (en) 2010-12-16 2023-01-18 Amgen (Europe) GmbH Controlled release oral dosage forms of poorly soluble drugs and uses thereof
DK2655621T3 (en) 2010-12-20 2018-08-13 Massachusetts Gen Hospital Polycomb-associated non-coding RNAS
US20140079722A1 (en) 2011-03-09 2014-03-20 Centrose, Llc Extracellular targeted drug conjugates
AU2012229300B2 (en) 2011-03-11 2017-04-20 Celgene Corporation Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione
KR101976219B1 (ko) 2011-04-15 2019-05-07 제이 파마 가부시끼가이샤 유방암의 바이오마커
EP3421496B1 (en) 2011-05-13 2024-08-07 Astellas Pharma Inc. Antibodies for treatment of cancer expressing claudin 6
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
MX369028B (es) 2011-10-04 2019-10-25 Invivis Pharmaceuticals Inc Anti-progestinas para ser usadas en un metodo para inhibir el crecimiento de un tumor susceptible a inhibición del crecimiento por anti-progestinas.
WO2013086379A2 (en) 2011-12-08 2013-06-13 Fundacion Sales Methods and compositions for treating antiprogestin-resistant cancers
US20130338016A1 (en) 2012-04-17 2013-12-19 Vala Sciences, Inc. Method For Integrated Pathology Diagnosis And Digital Biomarker Pattern Analysis
JP2015516155A (ja) 2012-04-27 2015-06-11 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 乳がん予後判定、プロゲステロン受容体サブタイプの予測および遺伝子発現に基づく抗プロゲスチン処置に対する応答の予測
US20150241432A1 (en) 2012-07-24 2015-08-27 Cedar-Sinai Medical Center Novel method to detect resistance to chemotherapy in patients with lung cancer
US20150320795A1 (en) 2012-12-13 2015-11-12 Roy JOSEE Compositions and methods comprising polyethylene glycol and magnesium for treatment of neuronal injury
CA2904116C (en) * 2013-03-12 2021-09-14 Arno Therapeutics Onapristone polymorphic forms and methods of use
US20140363425A1 (en) 2013-03-13 2014-12-11 J. Dinny Graham Systems and methods for identifying cancers having activated progesterone receptors
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
CN103483449A (zh) 2013-08-20 2014-01-01 东北农业大学 两种scFv抗体、其编码基因及其在制备治疗或预防鸡传染性法氏囊病制剂中的应用
CN106170701A (zh) 2014-04-08 2016-11-30 阿尔诺治疗公司 用于鉴定孕酮受体亚型的系统及方法
MX391191B (es) 2014-11-17 2025-03-21 Context Biopharma Inc Composiciones de liberación extendida de onapristona y métodos.
WO2016154203A1 (en) 2015-03-23 2016-09-29 Evestra, Inc. Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents
CA2998924A1 (en) 2015-09-25 2017-03-30 Context Biopharma Inc. Methods of making onapristone intermediates
US10548905B2 (en) 2015-12-15 2020-02-04 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
WO2017165315A1 (en) 2016-03-21 2017-09-28 Arno Therapeutics, Inc. Onapristone metabolite compositions and methods
CA3022961A1 (en) 2016-05-02 2017-11-09 Tetragenetics, Inc. Anti-kv1.3 antibodies, and methods of production and use thereof
WO2018067198A1 (en) 2016-10-03 2018-04-12 The Regents Of The University Of California Inhibitory antibodies and methods of use thereof

Also Published As

Publication number Publication date
AU2015350241B2 (en) 2021-05-20
US20230157960A1 (en) 2023-05-25
CN106999501A (zh) 2017-08-01
EP3247362A1 (en) 2017-11-29
US20210220279A1 (en) 2021-07-22
CN106999501B (zh) 2021-08-13
RU2017112748A (ru) 2018-12-19
AU2021218093A1 (en) 2021-09-09
WO2016081383A1 (en) 2016-05-26
AU2015350241A1 (en) 2017-05-04
EP3247362A4 (en) 2018-10-10
CA2966753A1 (en) 2016-05-26
JP2017537883A (ja) 2017-12-21
RU2017112748A3 (enExample) 2019-06-26
US11672762B2 (en) 2023-06-13
JP6655075B2 (ja) 2020-02-26
US10786461B2 (en) 2020-09-29
KR20170084086A (ko) 2017-07-19
HK1246653A1 (zh) 2018-09-14
MX2017005163A (es) 2018-01-18
CN113559075A (zh) 2021-10-29
US20160166583A1 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
PH12020550341A1 (en) Niraparib formulations
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
MX2020012310A (es) Formulaciones de liberacion prolongada de colchicina y metodos de uso de las mismas.
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
EA201792591A1 (ru) Фармацевтические препараты
PE20170773A1 (es) Formulaciones farmaceuticas, procesos para la preparacion, y metodos de uso
PH12015500823A1 (en) Modified release formulations for oprozomib
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
MA43876B1 (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
MX2022013450A (es) Formulaciones farmaceuticas.
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.
SA516370446B1 (ar) تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها
WO2020022976A3 (en) A formulation comprising dexketoprofen